Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin

Informație de încredere. Sprijin real.

Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.

Începe gratuitSunt părinteSunt specialist
Spațiu publicitar disponibil — bannerul mare de susSpațiu publicitar disponibil — bannerul mare de sus

Explorează temele

Caută tot →

Sănătate mintală și neurodezvoltare

AutismSpectrul autist și particularitățile asociate.223 de articole
ADHDAtenție, impulsivitate și hiperactivitate.202 articole
Sindrom DownDezvoltare și sprijin pentru sindromul Down.57 de articole
AnxietateÎngrijorare excesivă, tensiune, atacuri de panică.73 de articole
DepresieTristețe persistentă, lipsa energiei și a motivației.106 articole
AdicțiiDependențe de substanțe și comportamentale.135 de articole

Afecțiuni neurologice

DemențeBoala Alzheimer și alte forme de demență.73 de articole
AVC și AITAccident vascular cerebral și recuperare, la orice vârstă.64 de articole
Leziuni medulareLeziuni medulare, paraplegie și tetraplegie.55 de articole
EpilepsieCrize epileptice și managementul lor.127 de articole
ParkinsonBoala Parkinson și tulburări de mișcare.64 de articole
Scleroză multiplăScleroza multiplă și viața cu aceasta.71 de articole
Traumatisme cranio-cerebraleTraumatisme cranio-cerebrale și recuperare.81 de articole

Articole și ghiduri recomandate

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuDepresieÎncredere înaltă30.06.2026

Depression and Apathy: Examining an Overlooked Dimension in Major Depressive Disorder

This study examines apathy as a frequently underrecognized feature of major depressive disorder in 154 outpatients, finding apathy present in 48% of the sample and associated with higher depression severity, lower cognitive function, and reduced quality of life. The research identifies specific depressive symptoms—inability to feel and loss of interest—as the strongest predictors of apathy, suggesting it represents a distinct clinical dimension warranting greater clinical attention.

StudiuDepresieÎncredere înaltă30.06.2026

Dissociating Apathy, Depression and Anhedonia: A Machine Learning Analysis of Core Distinguishing Features

This study analyzed data from 4,578 participants across seven datasets to identify core symptoms that differentiate apathy, depression, and anhedonia, which are clinically overlapping conditions. Using machine learning and validated assessment scales, researchers identified a robust five-factor structure revealing three distinct apathy domains (behavioral, social, emotional) separate from depression and anhedonia, with 10 core symptoms achieving >90% accuracy in differentiating pure syndromes.

StudiuAdicțiiÎncredere înaltă30.06.2026

Psychotropic Medication Patterns in Adolescents and Young Adults with Opioid Use Disorder and Psychiatric Comorbidities

This retrospective cohort study analyzed medication prescribing patterns for 101 adolescents and young adults (mean age 18.5 years) with opioid use disorder and co-occurring psychiatric conditions, finding high rates of polypharmacy (79.2%), medication switching (91.2%), and treatment non-persistence. Depression, anxiety disorders, and ADHD were the most common psychiatric comorbidities, with non-persistence particularly prevalent in depression (63.2%) and bipolar disorder (66.7%).

StudiuDepresieÎncredere înaltă30.06.2026

Electroconvulsive Therapy for Depression Alters Mitochondrial Serum Metabolites

This study examined whether ECT—a highly effective treatment for severe, treatment-resistant depression—changes mitochondrial metabolism by measuring serum metabolites in 102 patients across three time points using NMR spectroscopy. ECT induced both acute metabolic changes (increased citrate, glucose, glutamine, pyruvate; decreased formate, phenylalanine) and sustained shifts in energy metabolism (increased alanine/pyruvate, decreased ketone bodies), with ketone body reduction associated with clinical improvement.

StudiuDepresieÎncredere înaltă30.06.2026

Tocilizumab versus Placebo for Treatment-Resistant Depression with Low-Grade Inflammation: A Randomized Triple-Blind Clinical Trial Protocol

This proof-of-concept trial examines whether IL-6 inhibition via tocilizumab can improve depressive symptoms and cognitive function in adults with treatment-resistant major depression who have elevated inflammation markers. The study randomizes 22 patients to a single tocilizumab infusion or placebo with follow-up assessments at days 7, 14, and 28, using healthy controls as biomarker comparators.